Real-world experience of dacomitinib in EGFR mutated advanced NSCLC: A single center experience from India.

被引：2
|
作者：
Biswas, Bivas [1 ]
Ganguly, Sandip [1 ]
Ghosh, Joydeep [1 ]
Roy, Somnath [1 ]
Bakshi, Rupsa [1 ]
Dabkara, Deepak [1 ]
机构：
[1] Tata Med Ctr, Kolkata, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21043
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience
    Biswas, B.
    Ganguly, S.
    Ghosh, J.
    Roy, S.
    Bhattacharjee, A.
    Bakshi, R.
    ANNALS OF ONCOLOGY, 2023, 34
  • [2] Toxicity profile of afatinib in advanced EGFR mutated NSCLC treatment: a real world single-center experience
    Mazzotta, M.
    Iacono, D.
    Lauro, S.
    Giusti, R.
    Marchetti, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Real-world outcomes and prognostic factors in uterine leiomyosarcom: A single center experience from India.
    Palo, Upasana
    Roy, Arunava
    Ghosh, Anik
    Mondal, Debapriya
    Chakraborti, Basumita
    Bhaumik, Jaydip
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17620 - E17620
  • [4] Real-world experience of ALK positive NSCLC from India
    Malhotra, M.
    Noronha, V.
    Joshi, A.
    Patil, V.
    Wadhwa, S.
    Prabhash, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 64 - 64
  • [5] Real-World Gefitinib 1st Line Treatment of Patients with Advanced NSCLC and EGFR Mutations - Serbian Single Center Experience
    Radosavljevic, D.
    Spasic, J.
    Ristic, M.
    Nikolic, V.
    Nikolic, N.
    Stanic, N.
    Djordjevic, F.
    Gavrilovic, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S899 - S899
  • [6] Real-world Experience of the Utility in Afatinib Therapy for Patients with EGFR-Mutant Advanced NSCLC
    Igawa, S.
    Ono, T.
    Kasajima, M.
    Yamada, K.
    Oguri, A.
    Kameda, A.
    Yamamoto, H.
    Kakegawa, M.
    Hiyoshi, Y.
    Kusuhara, S.
    Ozawa, T.
    Otani, S.
    Fukui, T.
    Mitsufuji, H.
    Masaru, K.
    Yokoba, M.
    Kubota, M.
    Sasaki, J.
    Naoki, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S611 - S611
  • [7] Real-World Evidence of EGFR Targeted Therapy in NSCLC- A Brief Report of Decade Long Single Center Experience
    Chougule, Anuradha
    Chandrani, Pratik
    Noronha, Vanita
    Pange, Priyanka
    Kale, Shrutikaa
    Nikam, Ankita
    Nambiar, Kavya
    Marchande, Dipika
    Durve, Arpana
    Gupta, Vinod
    Jagtap, Vinita
    Tiwrekar, Priyanka
    Menon, Nandini
    Joshi, Amit
    Kaushal, Rajeev
    Pai, Trupti
    Patil, Vijay Maruti
    Dutt, Amit
    Banavali, Shripad Dinanath
    Prabhash, Kumar
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (11):
  • [8] The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience
    Yan, Ningning
    Guo, Sanxing
    Huang, Siyuan
    Zhang, Huixian
    Li, Xingya
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience
    Cronin, Christopher
    Iqbal, Shahid
    Farooq, Abdul R.
    O'Dea, Pauline
    Burke, Louise
    O'Reilly, Seamus
    O'Mahony, Deirdre
    Power, Derek G.
    Bambury, Richard M.
    Collins, Dearbhaile C.
    LUNG CANCER MANAGEMENT, 2023, 12 (01)
  • [10] Molecular epidemiology of EGFR mutations in NSCLC: A single-center experience from India
    Ghosh, M.
    Shivakumar, Y.
    Balaram, G.
    Thomas, R.
    Dharman, B.
    Kowsik, P. V.
    Ghorpade, S. N.
    Nanjaiah, T. B.
    Patil, S.
    Naik, R.
    Kanakasetty, G. B.
    Thungappa, S. C.
    Poppareddy, S. H.
    Jayappa, S. Belagutti
    Bhattacharjee, S.
    Susheela, S. Papaiah
    Naseer, M. R.
    Sharma, A.
    Gunari, P. P.
    Ajaikumar, B. S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S124 - S125
12345